Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06397274
PHASE2

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

Sponsor: Steminent US, Inc.

View on ClinicalTrials.gov

Summary

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

Official title: A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia

Key Details

Gender

All

Age Range

20 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-06-01

Completion Date

2028-06-01

Last Updated

2024-05-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

Stemchymal

Patients will receive Stemchymal® through intravenous infusion

BIOLOGICAL

Placebo

Patients will receive Placebo through intravenous infusion